Interferon alfa-2b (Intron-A)

General information

Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways. Mechanism not fully understood.
Route: SC, IM, IV, intralesional
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Adult T-cell leukemia-lymphoma
• Chronic myelogenous leukemia
• Melanoma
• Multiple myeloma
• Neuroendocrine tumors
• Pancreatic NET
• Renal cell carcinoma
• Systemic mastocytosis

Diseases for which it was used

• Follicular lymphoma

Patient drug information

• Interferon alfa-2b (Intron-A) patient drug information (Chemocare)
• Interferon alfa-2b (Intron-A) patient drug information (UpToDate)

History of changes in FDA indication

• 6/4/1986: Initial FDA approval

Also known as

Caution, may also contain names for interferon beta, interferon gamma, or interferon alfa-2a.

Synonyms
Advaferon	Alfaferone	Berofor	Biogamma	Canferon A
Cytoferon	Egiferon	Feron	Fiblaferon	Frone
Finnferon-Alpha	Heberon Alfa R	Humoferon	IFN Alpha	Imufor
Imukin	INF	Inferax	Infergen	Inmutag
Interfero	Interferon Alfanative	Interferon Human	Interferon Leucocyticum	Interferon Lymphoblastoid
Interferonum Leucocyticum	Laroferon	Multiferon	Namalvin	OIF
Polyferon	Realdiron	Roceron-A	Sumiferon	Wellferon